Gail M Farfel Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Gail M Farfel.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Gail M Farfel. Gail M Farfel is Director in DURECT CORP ($DRRX) and Chief Clinical Dev & Reg Offic in MARINUS PHARMACEUTICALS INC ($MRNS) and EVP/Chief Development Officer in ZOGENIX, INC. ($ZGNX) and Director in AVROBIO, Inc. ($AVRO).
Latest Insider Trading Transactions of Gail M Farfel
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AVRO, DRRX, MRNS, ZGNX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 0.00 | 15,000 | 0 | 15,000 | |
| Mar 30 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 0.00 | 15,000 | 0 | 15,000 | |
| Mar 30 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 18.76 | 30,000 | 562,800 | 30,000 | |
| Mar 30 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 18.76 | 30,000 | 562,800 | 30,000 | |
| Mar 17 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 0.00 | 1,500 | 0 | 4,500 | |
| Mar 17 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 0.00 | 2,031 | 0 | 4,062 | |
| Mar 17 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 0.00 | 1,625 | 0 | 1,625 | |
| Mar 17 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Payment of Exercise | F | 20.70 | 542 | 11,219 | 14,776 | 15.3 K to 14.8 K (-3.54 %) |
| Mar 17 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 0.00 | 1,500 | 0 | 15,318 | 13.8 K to 15.3 K (+10.86 %) |
| Mar 17 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Payment of Exercise | F | 20.70 | 735 | 15,215 | 13,818 | 14.6 K to 13.8 K (-5.05 %) |
| Mar 17 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 0.00 | 2,031 | 0 | 14,553 | 12.5 K to 14.6 K (+16.22 %) |
| Mar 17 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Payment of Exercise | F | 20.70 | 587 | 12,151 | 12,522 | 13.1 K to 12.5 K (-4.48 %) |
| Mar 17 2021 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 0.00 | 1,625 | 0 | 13,109 | 11.5 K to 13.1 K (+14.15 %) |
| Oct 21 2020 | AVRO | AVROBIO, Inc. | Farfel Gail M | Director | Option Exercise | A | 16.14 | 28,000 | 451,920 | 28,000 | |
| Jun 29 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 0.00 | 8,750 | 0 | 0 | |
| Jun 29 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Payment of Exercise | F | 0.00 | 3,044 | 0 | 11,179 | 14.2 K to 11.2 K (-21.40 %) |
| Jun 29 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 0.00 | 8,750 | 0 | 14,223 | 5.5 K to 14.2 K (+159.88 %) |
| Jun 29 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 0.00 | 8,750 | 0 | 0 | |
| Jun 29 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Payment of Exercise | F | 0.00 | 3,044 | 0 | 11,179 | 14.2 K to 11.2 K (-21.40 %) |
| Jun 29 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 0.00 | 8,750 | 0 | 14,223 | 5.5 K to 14.2 K (+159.88 %) |
| Jun 18 2020 | DRRX | DURECT CORP | Farfel Gail M | Director | Option Exercise | A | 2.33 | 55,000 | 128,150 | 55,000 | |
| Jun 18 2020 | DRRX | DURECT CORP | Farfel Gail M | Director | Option Exercise | A | 2.33 | 55,000 | 128,150 | 55,000 | |
| May 13 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 28.21 | 2,573 | 72,584 | 5,048 | 7.6 K to 5 K (-33.76 %) |
| Mar 17 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 0.00 | 2,032 | 0 | 6,093 | |
| Mar 17 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 0.00 | 1,625 | 0 | 3,250 | |
| Mar 17 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Payment of Exercise | F | 22.01 | 696 | 15,319 | 7,621 | 8.3 K to 7.6 K (-8.37 %) |
| Mar 17 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 0.00 | 2,032 | 0 | 8,317 | 6.3 K to 8.3 K (+32.33 %) |
| Mar 17 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Payment of Exercise | F | 22.01 | 525 | 11,555 | 6,285 | 6.8 K to 6.3 K (-7.71 %) |
| Mar 17 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 0.00 | 1,625 | 0 | 6,810 | 5.2 K to 6.8 K (+31.34 %) |
| Mar 06 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
| Mar 06 2020 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 27.36 | 35,000 | 957,600 | 35,000 | |
| Aug 23 2019 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 52.00 | 3,446 | 179,192 | 4,891 | 8.3 K to 4.9 K (-41.33 %) |
| Apr 25 2019 | DRRX | DURECT CORP | Farfel Gail M | Director | Option Exercise | A | 0.57 | 70,000 | 39,788 | 70,000 | |
| Mar 26 2019 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 0.00 | 8,125 | 0 | 8,125 | |
| Mar 26 2019 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 52.66 | 63,750 | 3,357,075 | 63,750 | |
| Mar 19 2019 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 0.00 | 1,625 | 0 | 4,875 | |
| Mar 19 2019 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Payment of Exercise | F | 51.88 | 488 | 25,317 | 8,337 | 8.8 K to 8.3 K (-5.53 %) |
| Mar 19 2019 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 0.00 | 1,625 | 0 | 8,825 | 7.2 K to 8.8 K (+22.57 %) |
| Oct 09 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 13.96 | 6,961 | 97,176 | 30,289 | |
| Oct 09 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 43.74 | 1,961 | 85,766 | 7,143 | 9.1 K to 7.1 K (-21.54 %) |
| Oct 09 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 43.11 | 2,900 | 125,026 | 9,104 | 12 K to 9.1 K (-24.16 %) |
| Oct 09 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 42.92 | 2,100 | 90,137 | 12,004 | 14.1 K to 12 K (-14.89 %) |
| Oct 09 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 13.96 | 6,961 | 97,176 | 14,104 | 7.1 K to 14.1 K (+97.45 %) |
| Sep 05 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 13.96 | 7,000 | 97,720 | 37,250 | |
| Sep 05 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 48.21 | 2,300 | 110,872 | 7,143 | 9.4 K to 7.1 K (-24.36 %) |
| Sep 05 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 47.27 | 4,700 | 222,170 | 9,443 | 14.1 K to 9.4 K (-33.23 %) |
| Sep 05 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 13.96 | 7,000 | 97,720 | 14,143 | 7.1 K to 14.1 K (+98.00 %) |
| Aug 10 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 13.96 | 7,000 | 97,720 | 44,250 | |
| Aug 10 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 53.16 | 1,900 | 100,995 | 7,143 | 9 K to 7.1 K (-21.01 %) |
| Aug 10 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 52.42 | 5,100 | 267,318 | 9,043 | 14.1 K to 9 K (-36.06 %) |
| Aug 10 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 13.96 | 7,000 | 97,720 | 14,143 | 7.1 K to 14.1 K (+98.00 %) |
| Jun 13 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 13.96 | 5,000 | 69,800 | 51,250 | |
| Jun 13 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | M | 13.96 | 5,000 | 69,800 | 51,250 | |
| Jun 13 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 45.00 | 5,118 | 230,310 | 7,143 | 12.3 K to 7.1 K (-41.74 %) |
| Jun 13 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Sell | S | 45.00 | 5,118 | 230,310 | 7,143 | 12.3 K to 7.1 K (-41.74 %) |
| Jun 13 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 13.96 | 5,000 | 69,800 | 12,261 | 7.3 K to 12.3 K (+68.86 %) |
| Jun 13 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Buy | M | 13.96 | 5,000 | 69,800 | 12,261 | 7.3 K to 12.3 K (+68.86 %) |
| Mar 16 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 0.00 | 6,500 | 0 | 6,500 | |
| Mar 16 2018 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 42.65 | 40,000 | 1,706,000 | 40,000 | |
| Mar 16 2017 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 0.00 | 8,750 | 0 | 8,750 | |
| Mar 16 2017 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 10.20 | 52,500 | 535,500 | 52,500 | |
| Mar 16 2016 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 10.35 | 45,000 | 465,750 | 45,000 | |
| Oct 07 2015 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 13.32 | 15,000 | 199,800 | 15,000 | |
| Jul 06 2015 | ZGNX | ZOGENIX, INC. | Farfel Gail M | EVP/Chief Developme ... | Option Exercise | A | 13.96 | 56,250 | 785,250 | 56,250 | |
| Apr 23 2015 | MRNS | MARINUS PHARMACEUT ... | Farfel Gail M | Chief Clinical Dev ... | Option Exercise | M | 1.04 | 30,000 | 31,200 | 8,462 | |
| Apr 23 2015 | MRNS | MARINUS PHARMACEUT ... | Farfel Gail M | Chief Clinical Dev ... | Sell | S | 9.48 | 30,000 | 284,511 | 0 | 30 K to 0 (-100.00 %) |
| Apr 23 2015 | MRNS | MARINUS PHARMACEUT ... | Farfel Gail M | Chief Clinical Dev ... | Buy | M | 1.04 | 30,000 | 31,200 | 30,000 | 0 to 30 K |
Page: 1